Preeclampsia Diagnostics Market Size & Share, by Product (Instrument, Consumables); End-user (Hospitals, Clinics, Diagnostic Centers); Test (Blood Test, Urine Test) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 4412
  • Published Date: Oct 05, 2023
  • Report Format: PDF, PPT

Companies Dominating the Preeclampsia Diagnostics Landscape

top-features-companies
    • ACON Laboratories Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bio Rad Laboratories Inc.
    • BioCheck Inc.
    • bioMerieux SA
    • Cardinal Health Inc.
    • Diabetomics Inc.
    • F. Hoffmann La Roche Ltd.
    • Thermo Fisher Inc.
    • Biora Therapeutics Inc
    • Sysmex Corporation
    • Hitachi Ltd.
    • Fujirebio Diagnostics
    • Siemens Healthineers AG
    • Fujifilm Corporation

     


Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Thermo Fisher Scientific Inc., a world leader in serving science, announced in May 2023 that the U.S. Food and Drug Administration approved Thermo Scientific B·R·A·H· M·S PlGF plus KRYPTOR and B ·R·A·H . ·M·S sFlt-1 KRYPTOR novel biomarker, the first and only immunoassay to receive breakthrough designation and be validated for risk assessment and clinical management of preeclampsia, a serious complications of pregnancy.
  • Biora Therapeutics, Inc., a biotechnology company that reimagines therapy delivery, has entered into an agreement to license Avero Diagnostics' Preeclampsia Ruleout test previously carried out at Northwest Pathology Company for commercial development of the product.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4412
  • Published Date: Oct 05, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of pre-termed births, increasing innovative tests development are some of the major factors anticipated to drive the growth of the cell culture consumables market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024 - 2036.

The major players in the market are of Cardinal Health Inc., Diabetomics Inc., F. Hoffmann La Roche Ltd., Thermo Fisher Inc., Biora Therapeutics Inc, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying